losartan has been researched along with Angiogenesis, Pathologic in 23 studies
Losartan: An antagonist of ANGIOTENSIN TYPE 1 RECEPTOR with antihypertensive activity due to the reduced pressor effect of ANGIOTENSIN II.
losartan : A biphenylyltetrazole where a 1,1'-biphenyl group is attached at the 5-position and has an additional trisubstituted imidazol-1-ylmethyl group at the 4'-position
| Excerpt | Relevance | Reference |
|---|---|---|
| " Contrary to previous observations in higher-risk hypertensive patient groups, the treatment of essential hypertension with either losartan or hydrochlorothiazide did not affect indices of endothelial damage/dysfunction, angiogenesis or coagulation." | 9.11 | Effects of losartan versus hydrochlorothiazide on indices of endothelial damage/dysfunction, angiogenesis and tissue factor in essential hypertension. ( Beevers, DG; Chung, NA; Lip, G, 2004) |
| "Treatment with gemcitabine plus losartan further prolonged the survival time to 102." | 5.40 | Antitumor effect of angiotensin II type 1 receptor blocker losartan for orthotopic rat pancreatic adenocarcinoma. ( Hirooka, S; Inoue, K; Kim, S; Kwon, AH; Matsui, Y; Satoi, S; Toyokawa, H; Yamaki, S; Yamamoto, T; Yamao, J; Yanagimoto, H, 2014) |
| "Metoprolol treatment for 2 weeks improved LV systolic function." | 5.35 | Divergent effects of losartan and metoprolol on cardiac remodeling, c-kit+ cells, proliferation and apoptosis in the left ventricle after myocardial infarction. ( Kerkelä, R; Kubin, AM; Leskinen, H; Pieviläinen, O; Ruskoaho, H; Serpi, R; Soini, Y; Tenhunen, O; Tolonen, AM; Vaskivuo, T, 2009) |
| "Pretreatment with losartan decreased shunt-induced pulmonary vascular resistance and medial thickness by 51% and 35%, respectively." | 5.33 | Prevention of pulmonary vascular remodeling and of decreased BMPR-2 expression by losartan therapy in shunt-induced pulmonary hypertension. ( Brimioulle, S; Fesler, P; Hubloue, I; Huez, S; Kerbaul, F; Naeije, R; Remmelink, M; Rondelet, B; Salmon, I; Van Beneden, R, 2005) |
| " Contrary to previous observations in higher-risk hypertensive patient groups, the treatment of essential hypertension with either losartan or hydrochlorothiazide did not affect indices of endothelial damage/dysfunction, angiogenesis or coagulation." | 5.11 | Effects of losartan versus hydrochlorothiazide on indices of endothelial damage/dysfunction, angiogenesis and tissue factor in essential hypertension. ( Beevers, DG; Chung, NA; Lip, G, 2004) |
| "We evaluated the involvement of angiotensin II (AngII)-dependent pathways in melanoma growth, through the pharmacological blockage of AT1 receptor by the anti-hypertensive drug losartan (LOS)." | 3.76 | Inhibition of angiotensin II receptor 1 limits tumor-associated angiogenesis and attenuates growth of murine melanoma. ( Chammas, R; Freitas, HC; Fujihara, CK; Machado, CM; Mattar, AL; Nonogaki, S; Otake, AH; Zatz, R, 2010) |
| "Treatment with losartan, an angiotensin II receptor antagonist, decreased the collagen density and fiber length in the TIC, consistent with the known activity of this drug." | 1.43 | Implantable tissue isolation chambers for analyzing tumor dynamics in vivo. ( Bazou, D; Gruionu, G; Gruionu, LG; Huang, P; Maimon, N; Munn, LL; Onita-Lenco, M, 2016) |
| "Treatment with gemcitabine plus losartan further prolonged the survival time to 102." | 1.40 | Antitumor effect of angiotensin II type 1 receptor blocker losartan for orthotopic rat pancreatic adenocarcinoma. ( Hirooka, S; Inoue, K; Kim, S; Kwon, AH; Matsui, Y; Satoi, S; Toyokawa, H; Yamaki, S; Yamamoto, T; Yamao, J; Yanagimoto, H, 2014) |
| "Pancreatic cancer is one of the leading causes of cancer death, and represents a challenging chemotherapeutic problem." | 1.35 | Synergistic inhibitory effect of gemcitabine and angiotensin type-1 receptor blocker, losartan, on murine pancreatic tumor growth via anti-angiogenic activities. ( Fukui, H; Ikenaka, Y; Kaji, K; Kawaratani, H; Kitade, M; Namisaki, T; Noguchi, R; Tsujimoto, T; Yamazaki, M; Yanase, K; Yoshii, J; Yoshiji, H, 2009) |
| "Metoprolol treatment for 2 weeks improved LV systolic function." | 1.35 | Divergent effects of losartan and metoprolol on cardiac remodeling, c-kit+ cells, proliferation and apoptosis in the left ventricle after myocardial infarction. ( Kerkelä, R; Kubin, AM; Leskinen, H; Pieviläinen, O; Ruskoaho, H; Serpi, R; Soini, Y; Tenhunen, O; Tolonen, AM; Vaskivuo, T, 2009) |
| "Losartan-treated rats exhibited a significantly less marked reduction in vascular perfusion and a significantly lesser extent of tissue hypoxia." | 1.33 | The scar neovasculature after myocardial infarction in rats. ( Ansari, R; Kiani, MF; Postlethwaite, AE; Sun, Y; Wang, B; Weber, KT, 2005) |
| "Pretreatment with losartan decreased shunt-induced pulmonary vascular resistance and medial thickness by 51% and 35%, respectively." | 1.33 | Prevention of pulmonary vascular remodeling and of decreased BMPR-2 expression by losartan therapy in shunt-induced pulmonary hypertension. ( Brimioulle, S; Fesler, P; Hubloue, I; Huez, S; Kerbaul, F; Naeije, R; Remmelink, M; Rondelet, B; Salmon, I; Van Beneden, R, 2005) |
| "The development of hypertension and left ventricular hypertrophy was prevented by high- but not low-dose ramipril and was not affected by chronic bradykinin B2-receptor blockade." | 1.30 | Blockade of bradykinin B2 receptors prevents the increase in capillary density induced by chronic angiotensin-converting enzyme inhibitor treatment in stroke-prone spontaneously hypertensive rats. ( Amann, K; Gohlke, P; Kuwer, I; Mall, G; Schnell, A; Unger, T, 1997) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (4.35) | 18.2507 |
| 2000's | 9 (39.13) | 29.6817 |
| 2010's | 11 (47.83) | 24.3611 |
| 2020's | 2 (8.70) | 2.80 |
| Authors | Studies |
|---|---|
| Chiu, CZ | 1 |
| Wang, BW | 1 |
| Yu, YJ | 1 |
| Shyu, KG | 1 |
| Shen, Y | 1 |
| Wang, X | 1 |
| Lu, J | 1 |
| Salfenmoser, M | 1 |
| Wirsik, NM | 1 |
| Schleussner, N | 1 |
| Imle, A | 1 |
| Freire Valls, A | 1 |
| Radhakrishnan, P | 1 |
| Liang, J | 1 |
| Wang, G | 1 |
| Muley, T | 1 |
| Schneider, M | 1 |
| Ruiz de Almodovar, C | 1 |
| Diz-Muñoz, A | 1 |
| Schmidt, T | 1 |
| Si, W | 1 |
| Xie, W | 1 |
| Deng, W | 1 |
| Xiao, Y | 1 |
| Karnik, SS | 1 |
| Xu, C | 1 |
| Chen, Q | 1 |
| Wang, QK | 1 |
| Zhao, Y | 2 |
| Cao, J | 1 |
| Melamed, A | 1 |
| Worley, M | 1 |
| Gockley, A | 1 |
| Jones, D | 1 |
| Nia, HT | 1 |
| Zhang, Y | 1 |
| Stylianopoulos, T | 1 |
| Kumar, AS | 1 |
| Mpekris, F | 1 |
| Datta, M | 1 |
| Sun, Y | 2 |
| Wu, L | 1 |
| Gao, X | 1 |
| Yeku, O | 1 |
| Del Carmen, MG | 1 |
| Spriggs, DR | 1 |
| Jain, RK | 1 |
| Xu, L | 1 |
| Yoshiji, H | 3 |
| Noguchi, R | 3 |
| Namisaki, T | 3 |
| Moriya, K | 1 |
| Kitade, M | 3 |
| Aihara, Y | 2 |
| Douhara, A | 1 |
| Kawaratani, H | 3 |
| Nishimura, N | 1 |
| Fukui, H | 3 |
| Kim, S | 1 |
| Toyokawa, H | 1 |
| Yamao, J | 1 |
| Satoi, S | 1 |
| Yanagimoto, H | 1 |
| Yamamoto, T | 1 |
| Hirooka, S | 1 |
| Yamaki, S | 1 |
| Inoue, K | 1 |
| Matsui, Y | 1 |
| Kwon, AH | 1 |
| Araújo, WF | 1 |
| Naves, MA | 1 |
| Ravanini, JN | 1 |
| Schor, N | 1 |
| Teixeira, VP | 1 |
| Oh, E | 1 |
| Kim, JY | 1 |
| Cho, Y | 1 |
| An, H | 1 |
| Lee, N | 1 |
| Jo, H | 1 |
| Ban, C | 1 |
| Seo, JH | 1 |
| Gruionu, G | 1 |
| Bazou, D | 1 |
| Maimon, N | 1 |
| Onita-Lenco, M | 1 |
| Gruionu, LG | 1 |
| Huang, P | 1 |
| Munn, LL | 1 |
| Ikenaka, Y | 2 |
| Kaji, K | 2 |
| Yoshii, J | 2 |
| Yanase, K | 2 |
| Yamazaki, M | 1 |
| Tsujimoto, T | 2 |
| Otake, AH | 1 |
| Mattar, AL | 1 |
| Freitas, HC | 1 |
| Machado, CM | 1 |
| Nonogaki, S | 1 |
| Fujihara, CK | 1 |
| Zatz, R | 1 |
| Chammas, R | 1 |
| Serpi, R | 1 |
| Tolonen, AM | 1 |
| Tenhunen, O | 1 |
| Pieviläinen, O | 1 |
| Kubin, AM | 1 |
| Vaskivuo, T | 1 |
| Soini, Y | 1 |
| Kerkelä, R | 1 |
| Leskinen, H | 1 |
| Ruskoaho, H | 1 |
| Shirai, Y | 1 |
| Lawnicka, H | 1 |
| Ptasinska-Wnuk, D | 1 |
| Mucha, S | 1 |
| Kunert-Radek, J | 1 |
| Pawlikowski, M | 1 |
| Stepien, H | 1 |
| Chen, X | 1 |
| Meng, Q | 1 |
| Liu, M | 1 |
| Li, D | 1 |
| Yang, Y | 1 |
| Sun, L | 1 |
| Sui, G | 1 |
| Cai, L | 1 |
| Dong, X | 1 |
| Chung, NA | 1 |
| Beevers, DG | 1 |
| Lip, G | 1 |
| Wang, B | 1 |
| Ansari, R | 1 |
| Postlethwaite, AE | 1 |
| Weber, KT | 1 |
| Kiani, MF | 1 |
| Rondelet, B | 1 |
| Kerbaul, F | 1 |
| Van Beneden, R | 1 |
| Hubloue, I | 1 |
| Huez, S | 1 |
| Fesler, P | 1 |
| Remmelink, M | 1 |
| Brimioulle, S | 1 |
| Salmon, I | 1 |
| Naeije, R | 1 |
| Anandanadesan, R | 1 |
| Gong, Q | 1 |
| Chipitsyna, G | 1 |
| Witkiewicz, A | 1 |
| Yeo, CJ | 1 |
| Arafat, HA | 1 |
| Fukuda, D | 1 |
| Sata, M | 1 |
| Gohlke, P | 1 |
| Kuwer, I | 1 |
| Schnell, A | 1 |
| Amann, K | 1 |
| Mall, G | 1 |
| Unger, T | 1 |
| Machado, RD | 1 |
| Santos, RA | 1 |
| Andrade, SP | 1 |
| Rivera, E | 1 |
| Arrieta, O | 1 |
| Guevara, P | 1 |
| Duarte-Rojo, A | 1 |
| Sotelo, J | 1 |
1 trial available for losartan and Angiogenesis, Pathologic
| Article | Year |
|---|---|
Effects of losartan versus hydrochlorothiazide on indices of endothelial damage/dysfunction, angiogenesis and tissue factor in essential hypertension.
Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Diuretics; Endotheliu | 2004 |
22 other studies available for losartan and Angiogenesis, Pathologic
| Article | Year |
|---|---|
Hyperbaric oxygen activates visfatin expression and angiogenesis via angiotensin II and JNK pathway in hypoxic human coronary artery endothelial cells.
Topics: Angiotensin II; Anthracenes; Cell Movement; Cells, Cultured; Coronary Vessels; Cytokines; Endothelia | 2020 |
Reduction of Liver Metastasis Stiffness Improves Response to Bevacizumab in Metastatic Colorectal Cancer.
Topics: Angiogenesis Inhibitors; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhi | 2020 |
Angiotensin II increases angiogenesis by NF-κB-mediated transcriptional activation of angiogenic factor AGGF1.
Topics: Angiogenesis Inducing Agents; Angiogenic Proteins; Angiotensin II; Gene Expression Regulation; Human | 2018 |
Losartan treatment enhances chemotherapy efficacy and reduces ascites in ovarian cancer models by normalizing the tumor stroma.
Topics: Animals; Antineoplastic Agents; Ascites; Collagen; Disease Models, Animal; Drug Synergism; Extracell | 2019 |
Combination of sorafenib and angiotensin-II receptor blocker attenuates preneoplastic lesion development in a non-diabetic rat model of steatohepatitis.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Anticarcinogenic Agents; Antineoplastic Combined C | 2014 |
Antitumor effect of angiotensin II type 1 receptor blocker losartan for orthotopic rat pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Angiotensin II Type 1 Receptor Blockers; Animals; Antineoplastic Combined Chemothera | 2014 |
Renin-angiotensin system (RAS) blockade attenuates growth and metastatic potential of renal cell carcinoma in mice.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Captopril; Carc | 2015 |
Overexpression of angiotensin II type 1 receptor in breast cancer cells induces epithelial-mesenchymal transition and promotes tumor growth and angiogenesis.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Blotting, Western; Breast Neoplasms; Cadherins; Ce | 2016 |
Implantable tissue isolation chambers for analyzing tumor dynamics in vivo.
Topics: Animals; Biocompatible Materials; Blood Vessels; Brain; Collagen; Dimethylpolysiloxanes; Equipment D | 2016 |
Synergistic inhibitory effect of gemcitabine and angiotensin type-1 receptor blocker, losartan, on murine pancreatic tumor growth via anti-angiogenic activities.
Topics: Angiogenesis Inhibitors; Animals; Deoxycytidine; Drug Synergism; Gemcitabine; Losartan; Male; Mice; | 2009 |
Inhibition of angiotensin II receptor 1 limits tumor-associated angiogenesis and attenuates growth of murine melanoma.
Topics: Angiogenic Proteins; Angiotensin II Type 1 Receptor Blockers; Animals; Cell Line, Tumor; Female; Hum | 2010 |
Divergent effects of losartan and metoprolol on cardiac remodeling, c-kit+ cells, proliferation and apoptosis in the left ventricle after myocardial infarction.
Topics: Animals; Antihypertensive Agents; Apoptosis; Cell Count; Cell Proliferation; Heart Ventricles; Inter | 2009 |
Combination treatment of angiotensin II type I receptor blocker and new oral iron chelator attenuates progression of nonalcoholic steatohepatitis in rats.
Topics: Administration, Oral; Angiogenesis Inhibitors; Angiotensin II; Angiotensin II Type 1 Receptor Blocke | 2011 |
The involvement of angiotensin type 1 and type 2 receptors in estrogen-induced cell proliferation and vascular endothelial growth factor expression in the rat anterior pituitary.
Topics: Animals; Captopril; Cell Proliferation; Diethylstilbestrol; Estrogens; Gene Expression Regulation; H | 2012 |
Angiotensin II type 1 receptor antagonists inhibit cell proliferation and angiogenesis in breast cancer.
Topics: Adult; Aged; Angiogenesis Inhibitors; Angiotensin II Type 1 Receptor Blockers; Animals; Antineoplast | 2013 |
The scar neovasculature after myocardial infarction in rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Cicatrix; Losartan; Male; Myocardial Infarction; N | 2005 |
Prevention of pulmonary vascular remodeling and of decreased BMPR-2 expression by losartan therapy in shunt-induced pulmonary hypertension.
Topics: Animals; Antihypertensive Agents; Arteriovenous Shunt, Surgical; Gene Expression Regulation; Hyperte | 2005 |
Angiotensin II induces vascular endothelial growth factor in pancreatic cancer cells through an angiotensin II type 1 receptor and ERK1/2 signaling.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Blotting, Western; Carcinoma, Pancreatic Du | 2008 |
The renin-Angiotensin system: a potential modulator of endothelial progenitor cells.
Topics: Endothelium, Vascular; Humans; Hypertension; Losartan; Neovascularization, Pathologic; Renin-Angiote | 2007 |
Blockade of bradykinin B2 receptors prevents the increase in capillary density induced by chronic angiotensin-converting enzyme inhibitor treatment in stroke-prone spontaneously hypertensive rats.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Biphenyl Compounds; Bradykinin; Bradykinin Recept | 1997 |
Mechanisms of angiotensin-(1-7)-induced inhibition of angiogenesis.
Topics: Analysis of Variance; Angiogenesis Inhibitors; Angiotensin I; Angiotensin II; Angiotensin Receptor A | 2001 |
AT1 receptor is present in glioma cells; its blockage reduces the growth of rat glioma.
Topics: Angiotensin II; Animals; Antihypertensive Agents; Brain Neoplasms; Cell Division; Glioma; Losartan; | 2001 |